Petvivo Holdings Stock Price, News & Analysis

PetVivo Holdings (OTCQB: PETV), a biomedical company focused on therapeutic medical devices for animals, has scheduled its fiscal fourth quarter and full year 2025 earnings conference call for Monday, June 30, 2025, at 5:00 p.m. ET.

The company will release its financial results for the period ended March 31, 2025, before the conference call. Management will host a presentation followed by a Q&A session. Investors can access the call through a toll-free dial-in number or webcast, with a replay available afterward through the company's investor relations website.

PetVivo Holdings (OTCQB: PETV) has successfully completed its $5 million Series B Convertible Preferred Stock offering with the final $1 million purchase option exercise. The Series B shares are priced at $1.00 per share with a 1:1 conversion ratio to common stock.

The funding will support the commercialization of two key products: SPRYNG®, an injectable veterinary device for joint pain management, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use. PrecisePRP® offers consistent dosing with 4 billion platelets per vial and eliminates the need for blood draws or centrifugation.

PetVivo Holdings (OTCQB: PETV) has received $3 million through a partial exercise of a purchase option related to their Series B Convertible Preferred Stock offering. This is part of a larger $5 million equity financing deal, with $4 million total received to date and $1 million remaining to be exercised by June 26, 2025. The Series B shares are priced at $1.00 each with a 1:1 conversion rate to common stock. The funds will support the commercialization of SPRYNG, an injectable veterinary device for joint pain management, and PrecisePRP, an off-the-shelf platelet-rich plasma product for veterinary use. SPRYNG uses OsteoCushion Technology to restore joint mechanics, while PrecisePRP provides a consistent dose of 4 billion platelets per vial without requiring blood draws or centrifugation.

PetVivo Holdings (PETV) has announced a strategic partnership with Commonwealth, the ownership group behind Kentucky Derby winner Mage and Dubai World Cup Champion Country Grammer. The collaboration focuses on implementing PetVivo's SPRYNG with OsteoCushion Technology and Precise PRP products into Commonwealth's thoroughbred care protocols. SPRYNG is an intra-articular device for joint health, while Precise PRP is a first-in-class platelet-rich plasma product for elite equine athletes. The partnership includes clinical implementation, co-branded content, and educational initiatives to promote joint wellness awareness. Commonwealth will integrate these technologies as both preventative and treatment solutions for their high-performance horses, aligning with HISA's new welfare protocols for horse safety.

Digital Landia and PetVivo Holdings (OTCQB: PETV) have announced the launch of an invite-only MVP (minimum viable product) of Agentic.Pet, an autonomous pet artificial intelligence ecosystem. The platform, officially launched on May 23, 2025, is entering a stress-testing and debugging phase with select early adopters.

The MVP includes AI agents for veterinary diagnostics, behavioral analysis, and nutritional advising. Upcoming enhancements will feature pet facial recognition and specialized AI agents for blood tests, urine analysis, and radiological imaging. Access is currently limited to pet industry professionals and tech enthusiasts through an invite code system available at www.agenticpet.io.

PetVivo Holdings and PiezoBioMembrane have entered into a Master Services Agreement to develop innovative functional biomaterials. The collaboration combines PetVivo's expertise in extracellular matrix (ECM) biomaterials with PiezoBio's piezoelectric nanofibers technology. The partnership aims to create biomaterials that can be biologically activated through piezoelectric stimulation to enhance healing and regeneration of damaged tissue and bone in animals and humans. PetVivo's current product SPRYNG® with OsteoCushion® Technology demonstrates their capability in creating biocompatible materials that mimic mammalian tissue. PiezoBio contributes their biodegradable piezoelectric nanomaterial technology, which functions as a battery-less electrical stimulator to promote enhanced cell activity in implanted tissue or bone.

Digital Landia and PetVivo Holdings (OTCQB: PETV) announce the launch of AgenticPet.ai, an autonomous pet care AI ecosystem, on May 23, 2025. The platform utilizes self-learning multi-agent AI technology to revolutionize pet care through specialized AI agents that continuously evolve and provide insights into pet health and wellness. The platform features various specialized agents for veterinary diagnostics, behavior analysis, nutrition, and emotional wellness. AgenticPet.ai will offer three pricing tiers: a freemium model, Premium ($9.95/month), and Elite ($24.95/month). The company projects 100,000 freemium users within six months, with an expected 10% conversion to paid subscriptions, potentially generating $2 million in annual recurring revenue.

PetVivo Holdings (OTCQB: PETV) has signed a distribution agreement with Eq Especialidades to market and distribute Spryng™ with OsteoCushion™ technology throughout Mexico, effective April 1, 2025.

Spryng™ is an intra-articular injectable veterinary medical device containing sterilized, extra-cellular matrix microparticles. The technology works by adsorbing onto animal joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It aids in managing noninfectious joint pain conditions including joint instability, degenerative joint disease, and osteoarthritis.

This strategic partnership aims to expand PetVivo's presence in the Mexican animal health market, targeting both equine and companion animal segments.

PetVivo Holdings (OTCQB: PETV) has secured a $5 million equity financing through a Series B Convertible Preferred Stock offering. The company received an initial $600,000 on March 26, 2025, with the remaining $4.4 million expected within 60 days.

The funds will support the commercialization of two key products: SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary device using sterilized extra-cellular matrix microparticles for joint pain management, and Precise PRP®, an off-the-shelf platelet-rich plasma product for veterinary use.

Precise PRP® is notable for being leucoreduced and containing 4 billion platelets per vial at 500,000 platelets per microliter concentration, requiring no blood draw or centrifugation for administration in dogs and horses.